Why it's used
Telviran is used to treat viral infections. These include varicella-zoster (shingles), genital herpes, and chickenpox.
This drug doesn't cure herpes infections. The herpes virus can stay in your body for a long time and cause symptoms again later.
What Are Side Effects Associated with Using Telviran (Zovirax)?
Common side effects or health problems may include:
Other Telviran side effects, adverse reactions, or health problems may include:
This is not a complete list of side effects and other serious side effects or health problems may occur as a result of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.
El Telviran puede provocar efectos secundarios. DГgale a su doctor si cualquiera de estos sГntomas se vuelve severo o si no desaparece:
- malestar estomacal
- dolor, especialmente en las articulaciones
- pГ©rdida del cabello
- cambios en la visiГіn
The pharmacokinetics of Telviran after oral administration have been evaluated in 6 clinical studies involving 110 adult patients.
Q: How long is Telviran treatment?
A: How long Telviran (Zovirax) treatment is intended for depends upon the indication for use. Telviran is a prescription antiviral agent approved, by the U.S. Food and Drug Administration (FDA), for the acute treatment of herpes zoster (shingles), the treatment of initial episodes and the management of recurrent episodes of genital herpes and the treatment of chickenpox. Telviran treatment is approved for all indications for adults and for the treatment of chickenpox in children 2 year of age and older. For the acute treatment of shingles, the length of Telviran treatment is 7 to 10 days. The usual recommended adult dosage is 800 mg administered every 4 hours, 5 times daily. For the treatment of initial episodes of genital herpes, the length of Telviran treatment is 10 days. The usual recommended adult dosage is 200 mg administered every 4 hours, 5 times daily. For the management of recurrent episodes of genital herpes, there were two methods of administration of Telviran treatment evaluated in clinical trials. For intermittent therapy, the length of Telviran treatment is 5 days. Treatment should be initiated at the earliest sign or symptom of recurrence, known as a prodrome. The usual adult dosage is 200 mg administered every 4 hours, 5 times daily. The other option is chronic suppressive therapy in which Telviran treatment is used for up to 12 months and followed by re-evaluation by a health care provider to assess the need for continued treatment. The usual adult dosage is 400 mg twice daily. Alternative dosages may range from 200 mg 3 times daily to 200 mg 5 times daily, according to the prescribing information for Zovirax, the brand-name of Telviran. For the treatment of chickenpox for adults and children, the recommended length of Telviran treatment is 5 days. When treatment is required, it should be initiated at the earliest sign or symptom of chickenpox. The effectiveness of treatment initiated after 24 hours following the onset of symptoms is unknown. The usual dosage for adults and children weighing over 40 kg is 800 mg administered 4 times daily. The usual dosage for children 2 years of age and older is 20 mg/kg per dose administered 4 times daily.
Following oral administration, the mean plasma half-life of Telviran in volunteers and patients with normal renal function ranged from 2.5 to 3.3 hours. The mean renal excretion of unchanged drug accounts for 14.4% (8.6 to 19.8%) of the orally administered dose. The only urinary metabolite (identified by high performance liquid chromatography) is 9-guanine.
Telviran dissolved in 0.4% sterile saline was given by subcutaneous injection to Charles River CD (Sprague-Dawley) neonatal rats for 19 consecutive days, beginning on the 3rd post-partum day. The dose levels tested were 0, 5, 20 and 80 mg/kg body weight. There were 12 litters (each consisting of 5 male and 5 female neonates nursing the natural dam) at each dose level. The dams were not treated. Neonates were removed from each group for necropsy and microscopic evaluation of a wide variety of tissues, including eyes and multiple sections of brain, after they had been treated for 5, 12 or 19 days and after a 3-week postdose drug-free period (at which time they were 45 days of age). Hematologic (hemoglobin, packed cell volume, RBC, WBC and differential cell counts) and clinical chemistry (BUN) tests were done after 16 days of treatment and repeated 18 days after the last (19th) dose was given.
Blood was collected from some neonates 30 minutes after treatment on day 1, on day 9 and at the end of the dose period for the determination of concentrations of Telviran in plasma. The largest concentration of Telviran in plasma was 99.1 μg/mL (440.5 μM) found in pooled plasma collected from 6 female high-dose (80 mg/kg) neonates 30 minutes after the first dose was given. Treatment with Telviran did not increase mortality in the neonatal period.
Rats in the low-dose group gained as much body weight as the respective control rats. Significant (p
Want to thank TFD for its existence? Tell a friend about us, add a link to this page, or visit the webmaster's page for free fun content.